Day 1 afternoon session vote tallies clarified Friday for Thursday July 23, 2026: the FDA Pharmacy Compounding Advisory Committee (PCAC) voted 8-6 to recommend adding TB-500 (thymosin beta-4 fragment, marketed for wound healing and tissue repair) to the Section 503A Bulks List, and voted 7-5 with 2 abstentions to recommend adding MOTS-c (mitochondrial-derived peptide, nominated for obesity and metabolic disease). Both afternoon votes followed the morning session votes on BPC-157 (8-6, 1 abstention) and KPV (8-6, 1 abstention), making Thursday a clean sweep of all four Day-1 peptides. Every Day-1 win overrode the FDA career-staff briefing documents released June 29-30, which recommended against adding any of the seven peptides under review. Coverage across US News, ABC News, Bloomberg, The Hill, and Medical Daily converged on the framing that FDA career scientists were rebuked by the advisory panel on Day 1. TB-500 has been actively marketed alongside BPC-157 in 'tissue repair' and 'recovery' peptide-clinic protocols; MOTS-c has been marketed for metabolic health and mitochondrial function despite thin human clinical evidence.
The ASCO 2026 Annual Meeting opened today at McCormick Place Chicago, running through June 2, with more than 7,000 abstracts. The peptide-and-targeted-conjugate oncology cohort — pre-released in the May 21 abstract drop and the May 26 embargoed press briefing — now moves to live presentation. Friday May 29 brought the Corbus CRB-701 Nectin-4 ADC cervical/OPSCC data and the Dana-Farber/Bristol multiple myeloma and Pfizer lung cancer readouts. The peptide-mechanism slate across the meeting: Bicycle Therapeutics zelenectide pevedotin Duravelo-2 (bicyclic peptide-MMAE conjugate, oral June 1); Avacta AVA6000 FAP-Dox; BriaCell Bria-IMT cell-and-peptide immunotherapy; Sapience lucicebtide C/EBPβ antagonist (GBM); Aktis AKY-2519 B7-H3 miniprotein radioconjugate; Mayo TPIV200 folate-receptor peptide vaccine (TNBC, June 1); Telix ProstACT PSMA radioligand (June 1); plus the GLP-1 cancer slate (Abstract 3143, Roswell Park breast cancer). The targeted-conjugate categories — Nectin-4, PSMA, B7-H3, FAP, SSTR2 — are the densest peptide-adjacent oncology competition at the meeting.
EASL 2026 Day 1 in Barcelona delivered the most concentrated MASH-therapeutics data cycle of 2026. The peptide-mechanism cohort: Altimmune pemvidutide qFibrosis fibrosis regression (LBP-036), MetaVia DA-1726 48 mg Phase 1 noninvasive liver assessment, Novo Nordisk ESSENCE Japanese/menopausal subgroups. The non-peptide-mechanism cohort: Arrowhead ARO-INHBE RNAi (Activin E/ALK7 pathway), Galectin Therapeutics belapectin NAVIGATE (galectin-3 inhibitor), Sagimet Biosciences denifanstat + resmetirom combination (FASN inhibitor + Madrigal's Rezdiffra), Madrigal eight-poster Rezdiffra data drop on cardiovascular and portal hypertension markers. The combined cycle reframes MASH as a multi-mechanism battleground rather than a single-class indication — GLP-1/glucagon peptides compete against thyroid-hormone-receptor agonism, RNAi, galectin-3 inhibition, FASN inhibition, and emerging combinations. Thursday May 28 brings the Altimmune pemvidutide oral presentation at 17:00 CEST; Friday May 29 brings ASCO opening in Chicago to anchor the parallel peptide-oncology cycle.